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Gentamicin is an antibiotic that exhibits a broad
spectrum of activity and is particularly valuable in
severe sepsis. Its use is, however, restricted be-
cause of the development of ototoxicity and neph-
rotoxicity (for the latter, see review in Ref. 1). At
physiologic pH, the drug is highly charged and wa-
ter soluble, and therefore it is practically unable to
diffuse through biologic membranes.
Nephrotoxicity has been related to a selective ac-
cumulation of gentamicin in the renal cortex [2, 3].
Morphologic lesions of proximal tubules have been
documented in optic microscopy [4-6]. At the ultra-
structural level, the earliest lesions observed con-
cern the lysosomes, which show an accumulation of
myeloid bodies [7-9].
The mechanism of the gentamicin toxicity is,
however, unknown. In this paper, we present stud-
ies on the localization of the drug at the cellular and
subcellular levels, and on the enzymatic alterations
that develop during gentamicin treatment.
Autoradiography of microdissected nephrons.
Autoradiographic studies were performed on iso-
lated microdissected tubules by the technique of
Vandervalle et al [10]. The proximal tubular seg-
ments were divided in three groups: the initial
portion, corresponding to segments taken from the
first 3 mm following the glomerulus; the pars recta,
segments belonging to the straight proximal tubules,
corresponding to the 3 mm preceeding the begin-
fling of the thin descending limb of Henle; and the
mid portion, segments not belonging to the above
mentioned groups, that is, situated approximately
between the 4th and the 7th mm from the glomeru-
lus. Segments of the distal part of the tubule were
defined according to the following classification
[10]: thin descending limb (TDL), thin ascending
limb (TAL), thick medullary limb (MAL), cortical
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ascending limb (CAL), distal convoluted tubule
(DCT) (without distinction between bright and
granular portion of this segment), cortical collecting
tubule (CCT), and medullary collecting tubule
(MCT). Autoradiography was performed by dry
film technique [10].
Figure 1 shows the distribution of tritiated gen-
tamicin in the various segments of rabbit kidney
nephron 4 hours after a single injection (100 LCiJkg
of body wt; that is, 100 g of drug/kg). Thin-layer
chromatography showed that the intrarenal radio-
activity consisted only in true gentamicin, with a
relative contribution of the three major sub-
components (C1, Cia, and C2) similar to that of the
injected drug. No silver grain could be detected in
the glomerulus, and only very low amounts were
detected in all parts of the nephron beyond the
proximal tubule. The distribution of the drug among
this latter segment is, however, not homogenous:
the largest part of the drug is recovered in the pars
recta and a lesser amount in the early part of the
tubule. Autoradiography of kidney cortex slices
processed according to standard histologic tech-
niques showed only intracellular label. No silver
grains were seen in the tubular lumen and in blood
vessels.
Cell fractionation studies. Fractionation by den-
sity equilibration was performed on postnuclear su-
pernatants prepared in 0.25 M sucrose and 1 m
EDTA. The sample was placed at the top of a linear
sucrose gradient with densities extending from 1.10
to 1.30 glcm3. The gradient was centrifuged at
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Fig. 1. Incorporation of tritiated gentamicin in tubular cells. Sil-
ver grains were counted in ten areas at random, each 150 sm5
wide for each segment. The administration of tritiated drug was
performed on two animals, as described in the text. Individual
variations from nephron to nephron are expressed as the stan-
dard variation.
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Fig. 2. Cell fractionation studies on distribution of gentamicin.
Isopycnic centrifugation of a postnuclear supernatant was ob-
tained from isolated proximal tubules of a rabbit injected with
'4C-gentamicin and tritiated gentamicin, as indicated in the text.
The technique for isolating the tubules is derived from that of
Carlson et a! [44], and will be described in detail in a forthcoming
publication (Hjelle et al). Results are given as density distribu-
tion histograms, constructed following the method of Leighton
et al [45]. GLUTAN is y-glutamyl-transpeptidase; AAP, alanyl-
amino-peptidase; and CATH B, cathepsin B.
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Figure 2 shows the results of an experiment in
which an homogenate of isolated proximal tubules
from rabbit has been fractionated by isopycnic cen-
trifugation. This technique allows one to resolve, in
a clearcut fashion, lysosomes (detected by cathep-
sin B and N-acetyl-/3-glucosaminidase) from mito-
chondria (cytochrome oxidase) and the pericellular
membrane, especially the brush border (alanine ami-
nopeptidase and y-glutamyl-transpeptidase) (HjelleGranular (coi t) . .and Morin, unpublished). The animal was injected
Light (curt) with 14C-gentamicin (13 Ci; that is, 2 mg/kg of
Light (mad) body wt) and with tritiated gentamicin (26 pCi;
that is, 26 j.tg/kg of body wt), 6 hours and 45 mm
0 5 10 15 20 prior to the sacrifice, respectively.
The 14C-gentamicin injected 6 hours before sacri-
fice consistently and exclusively distributes in the
same manner as the two lysosomal enzymes. In a
control experiment where the homogenate was fro-
zen and thawed before centrifugation to disrupt
lysosomes, the antibiotic dissociated from the lyso-
somal enzymes and displayed a broad distribution
pattern similar to that of protein.
On the other hand, the tritiated gentamicin inject-
ed only 45 mm prior to sacrifice showed a slightly bi-
modal distribution, which is suggestive of an associ-
ation partly to lysosomes and to a lesser extent to
other subcellular structures, such as the brush bor-
der (alanine aminopeptidase).
Lysosomal structural latency. This was estimated
by measuring the free/total activity ratio of the N-
acetyl-f3-D-glucosaminidase, in a lysosomal prepa-
ration freshly isolated from cortex homogenate, as
____________ ____________ previously described [11, 12]. This ratio is assumed
to reflect the integrity of the lysosomal membrane
Density at the time of the assay [13]. A low ratio reflects
membrane integrity, and a high ratio reflects mem-
brane disruption and an increase of membrane per-
meability.
The variation of the latency of the lysosomal en-
zyme N-acetyl-f3-glucosaminidase is shown in Fig.
3. On a freshly isolated lysosomal fraction, we ob-
served that the treatment of the animals with gen-
tamicin results in a significant increase of the per-
centage of free activity, that is, the part of activity
of the enzyme that is demonstrable in the absence
of detergent. The addition of detergent induces the
total disruption of the lysosomal membrane. Similar
results are obtained with lysosomal fractions in-
cubated at 37° C for 60 mm, except that under those
conditions a higher level of free activity is observed
in the controls, due to the spontaneous rupture of
1.05 1.15 1.25 1.05 1.15 1.25 1.05 1.15 1.25
49,000 rpm for 2 hours in a vertical rotor (VTiSO;
Beckman Instruments, Palo Alto, California) with
the slow acceleration accessory and collected in 13
to 15 fractions, whose densities and weights were
recorded. Enzymes and constituents were assayed
after exposure of the fractions to 0.1% Triton X- 100
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Fig. 4. Structural latency of lysosomal N-acetyl-/3-glucosamini-
dase following gentamicin treatment (mean of four independent
experiments SEM).
lysosomes during the incubation [14, 15]. The ces-
sation of the treatment allows a recovery to control
values within approximately 8 days. The increase of
free activity of the N-acetyl-f3-glucosaminidase is
already significant after 8 days of treatment with 4
mg/kg gentamicin and is almost maximal at 50 mg/
kg (Fig. 4).
Correlation between biochemical and morpho-
logical changes. For biochemical analyses, kidney
cortices were dissected, dried on filter paper, and
frozen at _200 C until analysis. They were homoge-
nized (1/200 wt:vol) in distilled water by a Kontess
conical, sintered glass tissue grinder. The following
enzymes were assayed with chromogenic or fluoro-
Fig. 5. Level of the blood creatinine and the gentamicin content
of kidney cortex during gentamicin treatment and after ts'ith-
drawal of the drug (mean of four experiments SEM on Wistar
rats given 50mg/kg daily for 8 days).
genie substrates according to standard techniques
[16]. With 4-methyllumbelliferyl derivatives, acid a-
L-fucosidase, acid a-D-galactOsidase, acid a-D-man-
nosidase were assayed. With para-nitrophenol de-
rivative, N-acetyl-f3-D-glucosaminidase was as-
sayed. With para-nitranilide derivative, alanine
aminopeptidase and y-glutamyl transpeptidase were
assayed. Cathepsin B was measured with a-N-ben-
zoyl-D-L-arginir-2-naphtylamide [17]; sphingo-
myelinase was assayed with 2-hexadecanoyl amino-
4-nitrophenyl-phosphoryicholine [18]. True glucose
6-phosphatase was assayed with glucose 6-phos-
phate as substrate [16]. Proteins were measured by
the method of Lowry et a! [19] with bovine serum
albumin as standard. Gentamicin was assayed mi-
crobiologically with Bacillus subtilis as test orga-
nism.
In a first series of experiments, we have exam-
ined the development of biochemical lesions during
a treatment of Wistar rats with gentamicin, 50 mg/kg
for 8 days, and the recovery of these lesions follow-
ing cessation of treatment. Figure 5 shows that
blood creatinine rises after day 4, but returns to
control values within 15 days after treatment. The
elevation is highly significant and suggests promi-
nent renal failure. Histologic examination revealed
large zones of necrosis throughout the cortex. The
lesions had completely disappeared at day 30; that
is, 22 days after gentamicin withdrawal. Also as in-
dicated in Fig 5, the intracortical content of gen-
tamicin increases almost linearly up to day 4 and
then reaches a plateau value at a level of about 6 .tg
of antibiotic per milligram of protein; that is, about
0.9 mg/g of wet tissue. On discontinuation of the
treatment, the cortical content decreases rapidly to
about one third of the plateau value, and then much
more slowly during the next 40 days.
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Fig. 3. Effect ofgentamicin treatment on the structural latency of
lysosomal N-acetyl-f3-glucosaminidase (mean of four independ-
ent experiments SEM). Animals were injected with 50 mg/kg
gentamicin during the first 8 days (arrows).
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Fig. 6. Activity of sphingomyelinase of kidney cortex during and
after gentamicin treatment (50 mg/kg; 8 days; four experiments
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The activity of several lysosomal enzymes was
systematically measured in two sets of experi-
ments: (1) an 8-day treatment at 50 mg/kg followed
by gentamicin withdrawal, and (2) an 8-day treat-
ment at dosages varying from 0 to 100 mg/kg. Renal
function was evaluated by measuring the blood
creatinine. The most striking feature is the decrease
of the activity of the sphingomyelinase (Fig. 6), an
enzyme responsible for the intralysosomal break-
down of sphingomyelin [18, 21]. The effect is al-
ready significant after 2 to 4 days of treatment with
50 mg/kg or after 8 days with 4 mg/kg. Recovery of
the enzyme activity is rapid after cessation of treat-
ment. Another lysosomal activity affected is that of
cathepsin B, an acid thiol-dependent endopeptidase
of broad specificity [21]. Like sphingomyelinase, this
shows a decrease in activity. This effect is, how-
ever, seen only after 6 days and at doses of 50 mg/kg
or more. Other lysosomal enzymes assayed in this
study and several others, mainly glycosidases and
esterases, measured in similar experiments were
not significantly affected, with the exception of acid
a-galactosidase, the activity of which is slightly de-
creased.
The activity of y-glutamyl transpeptidase, an en-
zyme of the brush border [22], is significantly de-
creased. Surprisingly, this effect is already maxi-
10 20 40 5030
Time, days
Fig. 7 Activities of y-glutamyl-transpeptidase (brush border) and
of glucose 6-phosphatase (endoplasmic reticulum) of kidney cor-
texduring and after gentamicin treatment. The animals were in-
jected with 50 mg/kg gentamicin during the first 8 days (arrows).
The bottom part of the figure shows the DNA content of tissue.
(All values are the means SEM, N = 4 experiments).
mum after 4 mg/kg for 8 days; larger doses have no
further effect. Figure 7 shows, however, that the de-
crease of activity of y-glutamyl-transpeptidase is re-
lated to the duration of the treatment at 50 mg/kg.
Figure 7 indicates also that glucose 6-phospha-
tase (endoplasmic reticulum) is not affected. The
DNA-protein ratio shows little change, except for a
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transient but distinct rise immediately on gen-
tamicin withdrawal.
Discussion
Cellular and subcellular localization of intrarenal
gentamicin. The preferential association of gen-
tamicin with the kidney cortex has been known for
several years [2], but its cellular and intracellular
distribution has been largely overlooked. Recently,
several studies have pointed out that the drug dis-
tributes in a very discrete fashion within the cortex.
Just, Erdmann, and Haberman [23], Silverblatt and
Kuehn [24], and Kuhar, Mak, and Lietman [25]
showed an almost exclusive association of the drug
with the proximal tubules, with, however, a large
degree of heterogeneity among these structures.
The microdissection technique has allowed us to lo-
cate unambiguously gentamicin all along the neph-
ron. We demonstrate that the heterogeneity of con-
centration does not reflect an internephron varia-
tion of uptake, but rather a gradient of accumulation
along the proximal tubule of each individual neph-
ron. In accordance with other investigators, only
very low amounts of gentamicin are found in other
parts of the nephron, including the glomerulus.
The studies of Just, Erdmann, and Haberman [23]
and Silverblatt and Kuehn [24] have strongly sug-
gested that the intratubular gentamicin is not dis-
tributed throughout the cells, but rather is found ac-
cumulated within the lysosomes. Our biochemical
studies confirm clearly the localization of the intra-
renal gentamicin within the lysosomes, from which
it can be released only by disruption of the lysosom-
al membrane. This pattern is observed, however,
only a few hours after injection of drug, and shorter
periods of time yield less clearcut results. We inter-
pret the more complex distribution of gentamicin 45
mm after injection, as reflecting its mode of entry
within the tubular cells, which most likely is by ad-
sorptive pinocytosis from the tubular lumen. Ad-
sorptive pinocytosis is the process by which sub-
stances bind to the pericellular membrane and are
thereafter included into intracytoplasmic vacuoles
that arise from this membrane and that eventually
fuse with lysosomes. This process allows a very ef-
ficient uptake of a large number of exogenous com-
pounds into lysosomes [26, 27].
In accordance with this interpretation are the fol-
lowing. The autoradiographic studies cited above
show an association of the drug with the brush bor-
der and then with apical vesicles, prior to its intra-
lysosomal deposition. Our fractionation studies
agree with these findings, in that the amount of drug
that is clearly not associated with lysosomes 45 mm
after injection can be assigned to the brush border
(alanyl-aminopeptidase). The occurrence of an ad-
sorptive process at the level of the brush border is
all the more evident because binding of gentamicin
to this structure has been demonstrated in vitro
[28, 29]. The association constant and the number
of binding sites revealed by these studies are consis-
tent with a rate of uptake of the drug about 20-fold
faster than that of substances that enter cells by
fluid pinocytosis (that is, without prior binding to
the pericellular membrane, but through inclusion in
vesicles) such as inulin or PVP [30] (see also the
models of pinocytosis in Refs. 3 1—33). Interestingly
enough, a survey of the available data shows that
the renal uptake of gentamicin is 10- to 25-fold more
efficient than that of inulin or PVP [11, 34—36]. It
must also be stressed that pinocytosis is a vesicular
transport process; thus, no transmembrane trans-
port of the molecules is required for their final se-
questration in lysosomes. This is all the more im-
portant because gentamicin is a highly hydrophilic
substance.
The intracellular uptake and mntralysosomal accu-
mulation of gentamicin is not a phenomenon unique
to the kidney. Tulkens and Trouet [37] showed that
cultured rat fibroblasts readily take up gentamicin
and several other aminoglycosides as well; drugs
accumulate in lysosomes where they reach concen-
trations 100- to 200-fold larger than in the culture
fluid. A salient observation is that rat fibroblasts
take up gentamicin more slowly and less efficiently
than does the kidney, but they eventually accumu-
late very large amounts of drugs (up to 30 g or
more per milligram of cell protein; that is, 6 mg/g of
wet wt). The slower rate of uptake can almost com-
pletely be accounted for by the lack of binding sites
at the surface of fibroblasts, but the mechanism of
uptake (pinocytosis) seems similar in both cell types
(Morin and Tulkens, unpublished data).
Metabolic alterations induced by gentamicin.
Gentamicin has been reported to provoke charac-
teristic and dose-related anatomic renal changes
both in animals and in man [7-9]. The first lesions
observed concern the lysosomes that show a con-
spicuous accumulation of osmiophilic material, or-
ganized in a multilamellar and concentric dis-
position (myeloid bodies). Hruban, Slesers, and
Hopkins [43] have suggested that myeloid bodies
within lysosomes indicate an impairment of the deg-
radation of complex polar lipids. Such situations oc-
cur in several inborn enzyme defects [39]. For in-
stance, Tay-Sachs disease (deficiency of lysosomal
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f3-hexosaminidase A), Niemann-Pick disease (a de-
fect of sphingomyelinase), or Fabry disease (defi-
ciency of thermolabile a-galactosidase) result in the
intralysosomal accumulation of complex lipids
(mainly GM2 gangliosides, sphingomyelin and ce-
ramide dihexosides and trihexosides, respectively).
Morphologically, the accumulation of these lipids
bears some similarity to the images found by Kosek
et al [7] and his followers.
As mentioned above, gentamicin has been shown
to enter fibroblasts in culture. Using this model, Au-
bert-Tulkens, Van Hoof, and Tulkens [38] have
studied the cellular toxicity of the drug. When the
intracellular concentration reaches about 4 pg/mg
of cell protein (800 g/g of wet wt), lysosomes show
a conspicuous overloading with myeloid bodies,
similar in appearance to those observed in the kid-
ney. Other subcellular oganelles showed no lesion.
Assaying systematically for a large number of acid
hydrolases, Aubert-Tulkens et al [38] showed a con-
stant and highly significant decrease of the activity
of the lysosomal sphingomyelinase. Recent studies
from the same laboratory (Van Hoof, unpublished)
have also shown a decrease of the level of acid
phospholipase A (A1 + A2). Concomitantly, the to-
tal lipid phosphorus rises up to 170% of the control
value. Thin-layer chromatography indicates that the
concentration of all major phospholipids - is in-
creased without appreciable change in their relative
amounts. Thus, these observations are consistent
with the hypothesis that gentamicin impairs the
lysosomal catabolism of phospholipids, by decreas-
ing the activities of the corresponding hydrolases.
The molecular mechanism of this toxicity is under
investigation.
Our biochemical data with rat kidney cortices
suggest that the mechanism of gentamicin toxic ac-
tion may be similar to that reported for fibroblasts.
The activity of sphingomyelinase is significantly
decreased, under all conditions investigated, even
at low doses. It has, however, been difficult to dem-
onstrate unambiguously an accumulation of phos-
pholipids, due to the heterogeneity of the kidney
cortex and the much larger amount of nonlysosomal
phospholipids (mainly intracellular and pericellular
membranes) as compared with fibroblasts. Morpho-
logic studies in progress leave, however, no doubt
regarding the huge accumulation of myeloid bodies
in lysosomes, in an apparent correlation with the
decrease of sphingomyelinase activity. Also, we
have been unable to detect lesions in other sub-
cellular structures, as long as the cells do not exhib-
it signs of necrosis.
To the concept of gentamicin-induced phospho-
lipidosis, as developed by Aubert-Tulkens et a! [38]
for the fibroblasts, we should, however, add the
other features revealed by this work in kidney.
Cathepsin B and a-D-galactosidase, two other lyso-
somal enzymes, are also impaired. But this occurs
only at large doses and may be a secondary phe-
nomenon. Intralysosomal deposition of undigested
proteins and of galactocerebrosides [37] has not yet
been investigated.
We also have noted a sharp decrease of the activi-
ty of y-glutamy!transpeptidase and of alanyl-amino
peptidase (for the latter, data not shown), two en-
zymes of the brush border. This is consistent with
the increased urinary excretion of these enzymes
observed during aminoglycoside treatment (for re-
view, see Ref. 40). The significance of this finding in
relation with gentamicin-induced toxicity is, how-
ever, unclear because no dose-dependence of the
effect is observed. Finally, we could not demon-
strate any gross modification of the tissue protein
content.
Relation of lysosomal dysfunction with acute re-
nal failure. Elevation of the blood creatinine con-
centration is clearly observed for gentamicin dos-
ages above 20 mg/kg, at which an extensive cell ne-
crosis is observed in proximal tubules, but no
lesions are recorded in glomeruli or other parts of
the nephron. Thus, the decrease of the glomerular
filtration is most likely related to proximal tubule
injury. This is consistent with the concept that the
nephron constitutes a unit, all parts of which must
be functional for efficient activity.
Accepting this hypothesis, we may consider that
the site of the toxic action of gentamicin is exclu-
sively the proximal tubule. Lysosomal overloading
could lead to cell death, either because of mechani-
cal of chemical alteration of the lysosomal mem-
brane, or because of an impairment of some impor-
tant lysosomal function. In this connection, recent
studies from our laboratory using cultured human
fibroblasts have indicated that gentamicin readily
kills the cells when the intracellular concentration
reaches about 3 pg/mg of cell protein (600 g/g of
wet wt).
We cannot, however, exclude another site of tox-
icity of gentamicin besides lysosomes. For in-
stance, in vitro studies have shown that gentamicin
alters the respiratory control of isolated mito-
chondria. In vivo, however, no such effect could be
evidenced, nor was the localization of gentamicin
within the mitochondria demonstrated (either in
kidney or in cultured fibroblasts). Similarly, no oth-
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er site of storage, besides lysosomes, has been
unambiguously documented. In this respect, we
should point out the difficulty in interpretating the
cell fractionation data on animals injected with large
doses of gentamicin, or for prolonged periods, or
both.
As cells become necrotic, intralysosomal gen-
tamicin will be released and will reabsorb unspecifi-
cally to various structures. In addition, studies re-
ported so far [46, 47] are deficient in the strict mon-
itoring of the homogenization procedure, evaluation
of the integrity of the subcellular structures, and de-
termination of the actual composition of the isolated
fractions, three major prerequisites in tissue frac-
tionation (see Ref. 41 and 42). Our observation that
the latency of the lysosomal enzyme N-acetyl-/3-
glucosaminidase decreases during gentamicin treat-
ment reinforces this caveat, because it suggests an
alteration of the lysosomal membrane.
We have observed an apparent saturation of the
uptake of gentamicin, after 4 days of treatment with
50 mg/kg, concomitantly with the increase of blood
creatinine. This plateau could reflect a complex
equilibrium between (1) a decrease of the uptake
due to the decrease of glomerular filtration and (2)
an excretion of gentamicin from the kidney through
the elimination of necrotic cells. This should be fur-
ther investigated.
Summary. By autoradiography of microdissected
isolated nephrons, we show that gentamicin distrib-
utes almost exclusively in the proximal tubule,
where an increasing concentration gradient takes
place from the initial to the distal part. On isopycnic
centrifugation of homogenates from isolated tu-
bules, the drug is found exclusively associated with
the lysosomes 6 hours after injection. At a shorter
time, the distribution is slightly bimodal and consis-
tent with an association of part of the drug with
brush border. This agrees with the suggestion that
gentamicin enters cells and accumulates in lyso-
somes by absorptive pinocytosis.
In gentamicin-treated animals, we showed (1) a
decrease of the latency of lysosomes; (2) a decrease
of the activity of lysosomal sphingomyelinase and,
at large doses, of cathepsin B and a-D-galactosi-
dase; (3) a decrease of the activity of alanylamino-
peptidase and y-glutamyl-transpeptidase. Unlike
the others, the latter effect is not dose-related. All
these alterations showed complete reversibility
within 15 to 21 days after gentamicin withdrawal.
These findings are consistent with the proposal
that a central feature of the mechanism of gen-
tamicin nephrotoxicity involves the accumulation
of the drug in the lysosomes of the cells of the proxi-
mal tubule, leading to an extensive dysfunction of
these cells through (1) the subsequent inhibition of
the activities of the enzymes that are involved in the
degradation of polar lipids, (2) the alteration of the
properties of the lysosomal membrane per-
meability.
From in vitro studies on cultured cells (fibro-
blasts), these alterations of the cell metabolism
seem to be relevant for cell necrosis and cell death.
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